Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: Allogeneic hematopoietic cell transplantation (HCT) benefits many patients with acute myeloid leukemia (AML) in first remission. Hitherto, little attention has been given to the prognostic impact of pretransplantation minimal residual disease (MRD). Patients and Methods: We retrospectively studied 99 consecutive patients receiving myeloablative HCT for AML in first morphologic remission. Ten-color multiparametric flow cytometry (MFC) was performed on bone marrow aspirates before HCT. MRD was identified as a cell population showing deviation from normal antigen expression patterns compared with normal or regenerating marrow. Any level of residual disease was considered MRD positive. Results: Before HCT, 88 patients met morphologic criteria for complete remission (CR), whereas 11 had CR with incomplete blood count recovery (CRi). Twenty-four had MRD before HCT as determined by MFC. Two-year estimates of overall survival were 30.2% (range, 13.1% to 49.3%) and 76.6% (range, 64.4% to 85.1%) for MRD-positive and MRD-negative patients; 2-year estimates of relapse were 64.9% (range, 42.0% to 80.6%) and 17.6% (range, 9.5% to 27.9%). After adjustment for all or a subset of cytogenetic risk, secondary disease, incomplete blood count recovery, and abnormal karyotype pre-HCT, MRD-positive HCT was associated with increased overall mortality (hazard ratio [HR], 4.05; 95% CI, 1.90 to 8.62; P < .001) and relapse (HR, 8.49; 95% CI, 3.67 to 19.65; P < .001) relative to MRD-negative HCT. Conclusion: These data suggest that pre-HCT MRD is associated with increased risk of relapse and death after myeloablative HCT for AML in first morphologic CR, even after controlling for other risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Self-citationCheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Koreth, J., Schlenk, R., Kopecky, K. J., Honda, S., Sierra, J., Djulbegovic, B. J., Wadleigh, M., DeAngelo, D. J., Stone, R. M., Sakamaki, H., et al. (2009) · JAMA · doi:10.1001/jama.2009.813 · Cited by 886
Self-citationFlow cytometric immunophenotyping for hematologic neoplasms
Craig, F. E., & Foon, K. A. (2008) · Blood · doi:10.1182/blood-2007-11-120535 · Cited by 672
Cytogenetics in acute leukemia
Mrózek, K., Heerema, N. A., & Bloomfield, C. D. (2004) · Blood Reviews · doi:10.1016/s0268-960x(03)00040-7 · Cited by 659
Cornelissen, J. J., van Putten, W. L. J., Verdonck, L. F., Theobald, M., Jacky, E., Daenen, S. M. G., van Marwijk Kooy, M., Wijermans, P., Schouten, H., Huijgens, P. C., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025627 · Cited by 471
San Miguel, J. F., Vidriales, M. B., López-Berges, C., Dı́az-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M. J., Pérez, J. J., González, M., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1746 · Cited by 335
Sorror, M. L., Giralt, S., Sandmaier, B. M., De Lima, M., Shahjahan, M., Maloney, D. G., Deeg, H. J., Appelbaum, F. R., Storer, B., & Storb, R. (2007) · Blood · doi:10.1182/blood-2007-06-096966 · Cited by 326
Self-citation
Cited by
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Acute myeloid leukaemia in adults
Ferrara, F., & Schiffer, C. A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61727-9 · Cited by 563
Cornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhäuser, M., Juliusson, G., Råcil, Z., Rowe, J. M., Russell, N., Mohty, M., et al. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.150 · Cited by 400
Araki, D., Wood, B. L., Othus, M., Radich, J. P., Halpern, A. B., Zhou, Y., Mielcarek, M., Estey, E. H., Appelbaum, F. R., & Walter, R. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3826 · Cited by 400
Self-citationWalter, R. B., Buckley, S. A., Pagel, J. M., Wood, B. L., Storer, B. E., Sandmaier, B. M., Fang, M., Gyurkocza, B., Delaney, C., Radich, J. P., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506725 · Cited by 360
Self-citationEnasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Amatangelo, M. D., Quek, L., Shih, A., Stein, E. M., Roshal, M., David, M. D., Marteyn, B., Farnoud, N. R., de Botton, S., Bernard, O. A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779447 · Cited by 359
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Cornelissen, J. J., & Blaise, D. (2016) · Blood · doi:10.1182/blood-2015-07-604546 · Cited by 346
Immune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 341
Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation
Peled, J. U., Devlin, S. M., Staffas, A., Lumish, M., Khanin, R., Littmann, E. R., Ling, L., Kosuri, S., Maloy, M., Slingerland, J. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3348 · Cited by 325
Acute myeloid leukemia: 2013 update on risk‐stratification and management
Estey, E. H. (2013) · American Journal of Hematology · doi:10.1002/ajh.23404 · Cited by 277
Self-citationGrimwade, D., & Freeman, S. D. (2014) · Blood · doi:10.1182/blood-2014-05-577593 · Cited by 262
Chen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
Self-citationMeasurable Residual Disease in High-Risk Acute Myeloid Leukemia
Cluzeau, T., Lemoli, R. M., McCloskey, J., & Cooper, T. (2022) · Cancers · doi:10.3390/cancers14051278 · Cited by 13
“Walter 2011 [13] Myeloablative HCT • Median age: 45 y • N = 99 MFC in BM aspirates pre-HCT • 2-y OS: 77% • 2-y DFS: 75% • 2-y relapse: 18% • 2-y OS: 30% • 2-y DFS: 9% • 2-y relapse: 65% Not reported”
Metadata
- Authors
- Walter, R. B., Gooley, T. A., Wood, B. L., Milano, F., Fang, M., Sorror, M. L., Estey, E. H., Salter, A. I., Lansverk, E., Chien, J. W., Gopal, A. K., Appelbaum, F. R., & Pagel, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-20
- Volume
- 29
- Issue
- 9
- Pages
- 1190-1197
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107810465
- Cited by
- 405
- References
- 24
- FWCI
- 18.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.